Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Blood (2014) 124 (21): 621.

https://doi.org/10.1182/blood.V124.21.621.621

Published: 2014

Journal Articles

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

Andrew Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Uwe Hahn, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Anoop Enjeti, MBBS, MD FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Simon Z. He, MBBS,FRACP,FRCPA, Mark S Hertzberg, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 944.

https://doi.org/10.1182/blood.V124.21.944.944

Published: 2014

Journal Articles

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Susan Branford, PhD, David T Yeung, BSc, MBBS, FRACP, FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, Wendy T Parker, PhD, Jodi Braley, John F Seymour, MBBS, FRACP, PhD, Timothy P. Hughes, MD

Blood (2014) 124 (21): 816.

https://doi.org/10.1182/blood.V124.21.816.816

Published: 2014

Journal Articles

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Harry J Iland, MBBS FRACP FRCPA, Marnie Collins, BCom BSc(Hons), Mark S Hertzberg, MBBS PhDFRACP FRCPA, Michael Seldon, MBBS FRACP FRCPA, Andrew P Grigg, MBBS FRACP FRCPA MD, Frank Firkin, MBBS PhDFRACP FRCPA, Shane G Supple, BSc(Hons) PhD, Lynda J Campbell, Kenneth F Bradstock, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 375.

https://doi.org/10.1182/blood.V124.21.375.375

Published: 2014

Journal Articles

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Michael J. Dickinson, MBBS, FRACP, FRCPA, Kirsten Herbert, MD BSci(MD, FRACP, PhD, Caroline Sardjono, MDPhD, Thao Le, MDPhD, Diana Zannino, BSc, MSc, Colin Wood, John F Seymour, MBBS, FRACP, PhD, Melita Kenealy, MD, Miles Prince, MD FRACP, FRCPA

Blood (2014) 124 (21): 4657.

https://doi.org/10.1182/blood.V124.21.4657.4657

Published: 2014

Journal Articles

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

Blood (2014) 124 (21): 10.

https://doi.org/10.1182/blood.V124.21.10.10

Published: 2014

Journal Articles

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Andrew W. Roberts, MBBS, PhD, Shuo Ma, MD PhD, Danielle M. Brander, MD, Thomas J. Kipps, MD PhD, Jacqueline C. Barrientos, MD, Matthew S. Davids, MD, Mary Ann Anderson, PhD, Constantine Tam, MD, Tanita Mason-Bright, Nikita K. Rudersdorf, Lori Gressick, BS, Jianning Yang, PhD, Wijith Munasinghe, PhD, Ming Zhu, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD PhD, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 325.

https://doi.org/10.1182/blood.V124.21.325.325

Published: 2014

Journal Articles

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael J. Dickinson, MBBS, FRACP, FRCPA, Anupkumar George, MBBS FRACP FRCPA, Michael S Hofman, MBBS FRACP FAANMS, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, David Ritchie, MBBS, FRACP, FRCPA, PhD, H Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Dennis A Carney, MBBS FRACP FRCPA, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Constantine S Tam, MBBS, FRACP, FRCPA, MD, John F. Seymour, MBBS, FRACP, PhD

Blood (2013) 122 (21): 1796.

https://doi.org/10.1182/blood.V122.21.1796.1796

Published: 2013

Journal Articles

The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients

Matthew S. Davids, MD, John F. Seymour, MBBS, FRACP, PhD, John F. Gerecitano, MD, PhD, Brad S. Kahl, MD, John M. Pagel, MD, PhD, William G. Wierda, MD, PhD, Mary-Ann Anderson, Nikita K. Rudersdorf, Lori A. Gressick, BS, Nicholas P. Montalvo, MBA, CCRP, Jianning Yang, PhD, Todd A. Busman, MS, Martin Dunbar, DRPH, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2013) 122 (21): 1789.

https://doi.org/10.1182/blood.V122.21.1789.1789

Published: 2013

Journal Articles

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

Mary Ann Anderson, MBBS, FRACP, FRCPA, Constantine C.S. Tam, MBBS, FRACP, FRCPA, John F. Seymour, MBBS FRACP, Anthony Bell, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Surender Juneja, MD, David C.S. Huang, MB, BS, MRCP, PhD, Andrew W. Roberts, MBBS, PhD

Blood (2013) 122 (21): 1304.

https://doi.org/10.1182/blood.V122.21.1304.1304

Published: 2013

Journal Articles

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Animesh Pardanani, MBBS, PhD, Andrew W. Roberts, MBBS, PhD, John F. Seymour, MBBS, FRACP, PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Srdan Verstovsek, MD, PhD, Hagop M. Kantarjian, MD, Kebede Begna, MD, Hiroyuki Yoshitsugu, PhD, Toni Ann Gestone, PhD, Penny Phillips, PhD, Guan Xing, PhD, Gerson Peltz, MD, MPH, Matthew V Lorenzi, PhD, Leila Alland, MD, Adrian Woolfson, BM BCh, PhD, Ayalew Tefferi, MD

Blood (2013) 122 (21): 664.

https://doi.org/10.1182/blood.V122.21.664.664

Published: 2013

Journal Articles

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Blood (2013) 122 (21): 872.

https://doi.org/10.1182/blood.V122.21.872.872

Published: 2013

Journal Articles

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Srdan Verstovsek, MD, PhD, James P. Dean, MD, PhD, Paul Cernohous, MS, Rami S Komrokji, MD, John F. Seymour, MBBS, FRACP, PhD, Ruben A. Mesa, MD, Mary S Campbell, MD, Susan E. Caldwell, PhD, Lixia Wang, PhD, Han Myint, MD

Blood (2013) 122 (21): 395.

https://doi.org/10.1182/blood.V122.21.395.395

Published: 2013

Journal Articles

Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.

Emmanuel Bachy, MD, John F. Seymour, MBBS FRACP, Pierre Feugier, MD, PhD, Fritz Offner, Dolores Caballero, MD, Reda Bouabdallah, MD, Lars Möller Pedersen, MD, PhD, Pauline Brice, MD, David Belada, M.D., Ph.D., Luc Xerri, MD, PhD, Gilles Salles, MD

Blood (2012) 120 (21): 2649.

https://doi.org/10.1182/blood.V120.21.2649.2649

Published: 2012

Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, MD, Andrew W. Roberts, MD, PhD, Mary Ann Anderson, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., John F. Gerecitano, MD, PhD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Jianning Yang, PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, John F. Seymour, MBBS FRACP

Blood (2012) 120 (21): 304.

https://doi.org/10.1182/blood.V120.21.304.304

Published: 2012

Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

Blood (2012) 120 (21): 3923.

https://doi.org/10.1182/blood.V120.21.3923.3923

Published: 2012

Journal Articles

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

John F. Seymour, MBBS FRACP, Michael Pfreundshuh, MD, B. Coiffier, MD, Marek Trneny, MD, PhD, Laurie H. Sehn, MD, Eva Csinady

Blood (2012) 120 (21): 58.

https://doi.org/10.1182/blood.V120.21.58.58

Published: 2012

Journal Articles

Prolonged Progression Free Survival Does Not Relate to Quality of Response to Treatment with Thalidomide in Patients with Relapsed Multiple Myeloma (MM).

Hang Quach, MBBS, Miles H. Prince, MD MRACMA FRACPFRCPA, Linda Mileshkin, MBBS, John F. Seymour, MBBS, FRACP, PhD, David Westerman, MBBS, FRACP, FRCPA, Alvin D. Milner, PhD

Blood (2007) 110 (11): 2718.

https://doi.org/10.1182/blood.V110.11.2718.2718

Published: 2007

Journal Articles

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

David S. Ritchie, MBBS, PhD, FRACP, FRCPA, John F. Seymour, MBBS, FRACP, Sarah Thompson, RN, Michael McManus, MBBS, MD, MRCP, FRCR, Miles Prince, MBBS, MD, FRACP, FRCPA

Blood (2005) 106 (11): 5499.

https://doi.org/10.1182/blood.V106.11.5499.5499

Published: 2005

NARROW

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

The Adverse Effect of High Sokal Risk for First Line Imatinib Treated Patients Is Overcome By a Rapid Rate of BCR-ABL Decline Measured As Early As 1 Month of Treatment

Final Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 Trial: All- Trans Retinoic Acid (ATRA), Intravenous Arsenic Trioxide (ATO) and Idarubicin (IDA) As Initial Therapy for Acute Promyelocytic Leukemia (APL)

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy

The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients

Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction

BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Absence of Prognostic Impact Associated with the Use of Statins in Patients with Follicular Lymphoma in the Rituximab Era: An Exploratory Analysis From the PRIMA Study.

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

Prolonged Progression Free Survival Does Not Relate to Quality of Response to Treatment with Thalidomide in Patients with Relapsed Multiple Myeloma (MM).

Augmented Preparative Regimens Using Total Body Irradiation or BCNU Prior to Autologous Stem Cell Transplant (AuSCT) Are Well-Tolerated and Yield Substantial Rates of Progression-Free Survival in Patients with Poor Risk Hodgkin Lymphoma (HL) or Diffuse Large B-Cell Lymphoma (DLBCL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only